<SEC-DOCUMENT>0001193125-25-010511.txt : 20250122
<SEC-HEADER>0001193125-25-010511.hdr.sgml : 20250122
<ACCEPTANCE-DATETIME>20250122172503
ACCESSION NUMBER:		0001193125-25-010511
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250122
DATE AS OF CHANGE:		20250122

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Intra-Cellular Therapies, Inc.
		CENTRAL INDEX KEY:			0001567514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				364742850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36274
		FILM NUMBER:		25546945

	BUSINESS ADDRESS:	
		STREET 1:		135 ROUTE 202/206
		STREET 2:		SUITE 6
		CITY:			BEDMINSTER
		STATE:			NJ
		ZIP:			07921
		BUSINESS PHONE:		(646) 440-9333

	MAIL ADDRESS:	
		STREET 1:		135 ROUTE 202/206
		STREET 2:		SUITE 6
		CITY:			BEDMINSTER
		STATE:			NJ
		ZIP:			07921

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oneida Resources Corp.
		DATE OF NAME CHANGE:	20130122

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1229

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>d859518ddfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<HTML><HEAD>
<TITLE>DFAN14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&#8195; ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&#8194;&#9746; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Intra-Cellular Therapies, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Johnson&nbsp;&amp; Johnson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and <FONT
STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January 22, 2025, Johnson &amp; Johnson held its fourth quarter 2024 earnings call (the &#147;Earnings
Call&#148;). This filing contains excerpts of comments from (1) Joaquin Duato, Chairman and CEO of the Company, and (2) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine of the Company, and Tim Schmid, Executive
Vice President, Worldwide Chairman, MedTech of the Company, in ease case, relating to the Company&#146;s entry into a definitive agreement to acquire Intra-Cellular Therapies, Inc.&nbsp;(the &#147;Acquisition&#148;) from a transcript of the Earnings
Call. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following is an excerpt of comments from Joaquin Duato, Chairman and CEO of the Company, relating to the
Acquisition from a transcript of the Earnings Call. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Joaquin Duato, Chairman and CEO of </B><B>Johnson &amp; Johnson</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And building on our nearly 70-year legacy in neuroscience, we announced last week plans to acquire Intra-Cellular Therapies, a biopharmaceutical company
focused on the development and commercialization of therapeutics for central nervous system disorders. This unique opportunity to add Intra-Cellular Therapies reflect our commitment to transforming care and advancing research in mental health. It
also further solidifies sales growth above analyst expectations now and through the remainder of the decade. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">. . . </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And finally, I want to underline that both Abiomed and Shockwave are progressing really well ahead of the deal model, delivering on our financial commitments
there and that we are looking forward upon closure to start working on the Intra-Cellular acquisition, which is an opportunity to reinforce our position of leadership in the neuroscience space, which has been always a strength of Johnson &amp;
Johnson and also an opportunity overall to fortify revenue projections that you have looking today and also into the future. Thank you. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following is an excerpt of comments from Jennifer Taubert, Executive Vice President, Worldwide Chairman,
Innovative Medicine of the Company, and Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech of the Company, relating to the Acquisition from a transcript of the Earnings Call. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alexandria Hammond, Wolfe Research</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks so much for
taking the question and congrats on the Intra-Cellular deal last week. For CAPLYTA, how should we be thinking about the cadence of sales growth to the forecasted sales of $5 billion? And I guess on the acquisition, should we expect a
deprioritization of seltorexant and aticaprant? Thank you so much. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine
of Johnson &amp; Johnson </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks so much for the question. And we are so excited to be able to welcome the Intra-Cellular colleagues to Johnson &amp;
Johnson. They have done an extraordinary job, both in developing CAPLYTA and their pipeline, but also commercializing and bringing CAPLYTA to patients currently for schizophrenia as well as for bipolar 1 and bipolar 2 depression. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I think you can take a look at their current sales trajectory, which is a really nice growth curve and then also take into account the filing that done for a
MDD, major depressive disorder. The filing has been done with the regulatory authorities that we anticipate approval for later in the year. An MDD, we believe to ultimately be the largest of those three indications for CAPLYTA. And so we think that
that will be an additional catalyst for growth, so you can factor that into your thinking. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We&#146;re really excited about CAPLYTA. I know the company had
guided to it being a $5 billion-plus asset. We definitely think that it will be as well and think that together, we&#146;re going to be able to do even more for patients with mental health issues. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We&#146;re also really excited about their pipeline and 1284 and potential in Alzheimer&#146;s psychosis, general anxiety disorder and others. So we see
Intra-Cellular as both in near term as well as long-term growth catalyst for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech of
Johnson &amp; Johnson </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. About your question, though, around whether we&#146;ll do you prioritize other things in the portfolio, absolutely not.
Let me just remind everyone that depression is a very heterogeneous disorder, and it&#146;s not a disease that accommodates to a one size fits all. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We see
each of these molecules that we&#146;re developing, having unique mechanisms that can play in different subpopulations. And we&#146;re developing those aticaprant, seltorexant, for example, using a precision neuroscience strategy. So we see this
broad portfolio, which includes, of course, SPRAVATO as repertoire of different mechanisms we can bring to bear. The 260 million people worldwide that suffer from chronic depression. It&#146;s the leading cause of disability and more than 30% of
those do not get relief from the ongoing medicines. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The other thing that I really like about our portfolio is the side effect profiles are so benign
compared to the standard of care. With all four of the mechanisms, whether it&#146;s CAPLYTA, which we hope to welcome into the portfolio, whether it&#146;s an aticaprant, seltorexant, or SPRAVATO, you don&#146;t have weight gain, you don&#146;t
have sexual dysfunction. You don&#146;t have the tardive dyskinesia or extrapyramidal effects that are so common with many of the medicines today. So this is really exciting for us. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cautions Concerning Forward-Looking Statements </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains &#147;forward-looking statements&#148; regarding the acquisition of Intra-Cellular Therapies, Inc. (&#147;ITCI&#148;) by
Johnson&nbsp;&amp; Johnson. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson&nbsp;&amp; Johnson or ITCI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risks and
uncertainties include, but are not limited to: the risk that the closing conditions for the acquisition will not be satisfied, including the risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act will not be obtained; uncertainty
as to the percentage of ITCI stockholders that will vote to approve the proposed transaction at the ITCI stockholder meeting; the possibility that the transaction will not be completed in the expected timeframe or at all; potential adverse effects
to the businesses of Johnson&nbsp;&amp; Johnson or ITCI during the pendency of the transaction, such as employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the transaction,
including resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or
regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors;
challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health
care services and products; and trends toward health care cost containment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there will be risks and uncertainties related to the ability of
the Johnson&nbsp;&amp; Johnson family of companies to successfully integrate the programs, products, technologies and employees/operations and clinical work of ITCI. A further list and description of these risks, uncertainties and other factors and
the general risks associated with the respective businesses of Johnson&nbsp;&amp; Johnson and ITCI can be found in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2023, filed with the SEC on February&nbsp;16, 2024, including in the sections captioned &#147;Cautionary Note Regarding Forward-Looking Statements&#148; and &#147;Item 1A. Risk Factors,&#148; and in Johnson&nbsp;&amp;
Johnson&#146;s most recently filed Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and Johnson&nbsp;&amp; Johnson&#146;s subsequent filings with the SEC and in ITCI&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023, filed with the SEC on February&nbsp;22, 2024, including in the sections captioned &#147;Cautionary Statement Regarding Forward-Looking Statements&#148;
and &#147;Item 1A. Risk Factors,&#148; and in ITCI&#146;s most recently filed Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and ITCI&#146;s subsequent filings with the SEC. Copies of these filings, as well as subsequent
filings, are available online at www.sec.gov, www.jnj.com, www.intracellulartherapies.com or on request from Johnson&nbsp;&amp; Johnson or ITCI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither
Johnson&nbsp;&amp; Johnson nor ITCI undertakes to update any forward-looking statement as a result of new information or future events or developments, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Participants in the Solicitation </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp;
Johnson and ITCI and certain of their respective directors and executive officers, under SEC rules, may be deemed to be &#147;participants&#148; in the solicitation of proxies from stockholders of ITCI in connection with the proposed transaction.
Information about Johnson&nbsp;&amp; Johnson&#146;s directors and executive officers is available in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023,
which was filed with the SEC on February&nbsp;16, 2024, and Johnson&nbsp;&amp; Johnson&#146;s definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on March&nbsp;13, 2024. Information about ITCI&#146;s
directors and executive officers is available in ITCI&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, which was filed with the SEC on February&nbsp;22, 2024, and ITCI&#146;s
definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April&nbsp;29, 2024. To the extent holdings of Johnson&nbsp;&amp; Johnson&#146;s or ITCI&#146;s securities by their respective directors or
executive officers have changed since the amounts set forth in such 2024 proxy statements, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with
the SEC, including the Form 3 filed by Sanjeev Narula on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024097291/xslF345X02/ownership.xml">August<U></U>&nbsp;
14, 2024</A> and the Form 4s filed by: Sharon Mates on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/xslF345X05/ownership.xml">August<U></U>&nbsp;
23, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/xslF345X05/ownership.xml">August<U></U>&nbsp;
28, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/xslF345X05/ownership.xml">August<U></U>&nbsp;
30, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/xslF345X05/ownership.xml">December<U></U>&nbsp;
6, 2024</A>; Joel S. Marcus on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075079/xslF345X05/ownership.xml">June<U></U>&nbsp;
18, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077469/xslF345X05/ownership.xml">June<U></U>&nbsp;
25, 2024</A>; Rory B. Riggs on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075081/xslF345X05/ownership.xml">June<U></U>&nbsp;
18, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077468/xslF345X05/ownership.xml">June<U></U>&nbsp;
25, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024080986/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024111766/xslF345X05/ownership.xml">October<U></U>&nbsp;
2, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024114785/xslF345X05/ownership.xml">October<U></U>&nbsp;
15, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025001440/xslF345X05/ownership.xml">January<U></U>&nbsp;
3, 2025</A>; Eduardo Rene Salas on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075082/xslF345X05/ownership.xml">June<U></U>&nbsp;
18, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077470/xslF345X05/ownership.xml">June<U></U>&nbsp;
25, 2024</A>; Robert L. Van Nostrand on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075077/xslF345X05/ownership.xml">June<U></U>&nbsp;
18, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024076380/xslF345X05/ownership.xml">June<U></U>&nbsp;
21, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077472/xslF345X05/ownership.xml">June<U></U>&nbsp;
25, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024080987/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2024</A>; Michael Halstead on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024127275/xslF345X05/ownership.xml">November<U></U>&nbsp;
14, 2024</A>; Mark Neumann on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024099258/xslF345X05/ownership.xml">August<U></U>&nbsp;
20, 2024</A>; and Sanjeev Narula on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024097292/xslF345X05/ownership.xml">August<U></U>&nbsp;14, 2024</A>. Investors and stockholders of ITCI are or will be able to obtain these documents
free of charge from the SEC&#146;s website at www.sec.gov, from Johnson&nbsp;&amp; Johnson on Johnson&nbsp;&amp; Johnson&#146;s website at www.jnj.com, from ITCI on ITCI&#146;s website at www.intracellulartherapies.com or on request from
Johnson&nbsp;&amp; Johnson or ITCI. Additional information concerning the interests of ITCI&#146;s participants in the solicitation, which may, in some cases, be different than those of ITCI&#146;s stockholders generally, will be set forth in
ITCI&#146;s proxy statement relating to the proposed transaction when it becomes available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Additional Information and Where to Find It </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication may be deemed to be solicitation material in respect of the proposed acquisition of ITCI by Johnson&nbsp;&amp; Johnson. In connection with
the proposed transaction, ITCI intends to file relevant materials with the U.S. Securities and Exchange Commission (&#147;SEC&#148;), including ITCI&#146;s proxy statement in preliminary and definitive form. INVESTORS AND STOCKHOLDERS OF ITCI ARE
URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING ITCI&#146;s PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED
TRANSACTION. Investors and stockholders of ITCI are or will be able to obtain these materials (when they are available) free of charge at the SEC&#146;s website at www.sec.gov, or free of charge from ITCI&#146;s website at
www.intracellulartherapies.com. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
